Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Science, Technology & Human Values
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mackenzie, M.
Right arrow Articles by Cambrosio, A.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Patents and Free Scientific Information in Biotechnology: Making Monoclonal Antibodies Proprietary

Michael Mackenzie

University of Ottawa

Peter Keating

Concordia University

Alberto Cambrosio

Université du Québec à Montréal

There has been some concern m recent years that economic interests in the biotechnology area could, particularly through patenting, have a constricting influence on scientific research. Despite this concern, there have been no studies of this phenomenon beyond isolated cases. In this article we examine the evolution of the biomedical field of hybridoma/monoclonal antibody research with detailed examples of the three types of patent claims that have emerged there—basic claims, claims on application techniques, and claims on specific antibodies. We analyze the impact of these claims and their legal histories on (1) the free flow of scientific information and, (2) the activity of scientific researchers. We conclude that such patent claims present severe restrictions for both, not only in the monoclonal area but in general, amounting to a subtle but significant shift in the political economy of science and technology.

Science, Technology & Human Values, Vol. 15, No. 1, 65-83 (1990)
DOI: 10.1177/016224399001500108
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Science Technology Human ValuesHome page
D. L. Kleinman
Untangling Context: Understanding a University Laboratory in the Commercial World
Science Technology Human Values, July 1, 1998; 23(3): 285 - 314.
[Abstract] [PDF]

Home page
 Science Technology Human ValuesHome page
K. Packer and A. Webster
Patenting Culture in Science: Reinventing the Scientific Wheel of Credibility
Science Technology Human Values, October 1, 1996; 21(4): 427 - 453.
[Abstract] [PDF]

Home page
 Science CommunicationHome page
S. Hilgartner and S. I. Brandt-Rauf
Data Access, Ownership, and Control: Toward Empirical Studies of Access Practices
Science Communication, June 1, 1994; 15(4): 355 - 372.
[Abstract]